Enanta Pharma slips on downbeat Q4 revenue

Enanta Pharmaceuticals

22/11/2022 16:16

** Shares of drug developer Enanta Pharmaceuticals Inc
 ENTA.O  fall 7.5% to $42.9
    ** Co late on Monday posted 13.8% fall in Q4 revenue to
$20.32 mln, below analysts' estimates of $22.9 mln - Refinitiv 
    ** Co reported its loss widened to $121.8 mln, or $5.91 per
share, for the year
    ** Says cash, cash equivalents and marketable securities
totaled $278.5 mln as of September 30, 2022
    ** ENTA sees cash runway to be sufficient to meet expected
requirements for existing business and developmental programs
into Q4 of fiscal 2024    
    ** Including session's fall, stock is down 42.6% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))